Fig. 4 | Scientific Reports

Fig. 4

From: Association of ANXA3 methylation with clinical outcomes of glucocorticoid therapy in patients with hepatitis B virus-related acute-on-chronic liver failure

Fig. 4

Dynamic changes for mRNA and methylation levels of ANXA3 in survivor and non-survivor groups of HBV-ACLF patients who received glucocorticoid therapy and conventional medical treatment. (A–C) The mRNA expression levels of ANXA3 in the survivor and non-survivor groups receiving GC therapy at days 0, 7, and 28. (E-G) The methylation levels of ANXA3 in the survivor and non-survivor groups receiving GC therapy at days 0, 7, and 28. (D) The mRNA expression levels of ANXA3 in the survivor and non-survivor groups receiving CM treatment at days 0, 7, and 28. (H) The methylation levels of ANXA3 in the survivor and non-survivor groups receiving CM treatment at days 0, 7, and 28. *p < 0.05. GC: glucocorticoid, CM: conventional medical.

Back to article page